MX2021007460A - Peptidos para el tratamiento y prevencion de diabetes y trastornos asociados. - Google Patents

Peptidos para el tratamiento y prevencion de diabetes y trastornos asociados.

Info

Publication number
MX2021007460A
MX2021007460A MX2021007460A MX2021007460A MX2021007460A MX 2021007460 A MX2021007460 A MX 2021007460A MX 2021007460 A MX2021007460 A MX 2021007460A MX 2021007460 A MX2021007460 A MX 2021007460A MX 2021007460 A MX2021007460 A MX 2021007460A
Authority
MX
Mexico
Prior art keywords
diabetes
peptides
treatment
prevention
associated disorders
Prior art date
Application number
MX2021007460A
Other languages
English (en)
Inventor
Vincent Marion
Original Assignee
Univ Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Strasbourg filed Critical Univ Strasbourg
Publication of MX2021007460A publication Critical patent/MX2021007460A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4866Protein C (3.4.21.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6464Protein C (3.4.21.69)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013Protein kinase C (2.7.11.13)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21069Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención se refiere a péptidos para el tratamiento de la diabetes y trastornos asociados.
MX2021007460A 2018-12-21 2019-12-20 Peptidos para el tratamiento y prevencion de diabetes y trastornos asociados. MX2021007460A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306794 2018-12-21
PCT/EP2019/086573 WO2020127904A1 (en) 2018-12-21 2019-12-20 Peptides for treatment and prevention of diabetes and associated disorders

Publications (1)

Publication Number Publication Date
MX2021007460A true MX2021007460A (es) 2022-11-15

Family

ID=65200524

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007460A MX2021007460A (es) 2018-12-21 2019-12-20 Peptidos para el tratamiento y prevencion de diabetes y trastornos asociados.

Country Status (25)

Country Link
US (1) US20220133860A1 (es)
EP (2) EP4233890A3 (es)
JP (2) JP7335337B2 (es)
KR (2) KR102555817B1 (es)
CN (2) CN116196399A (es)
AU (1) AU2019408382A1 (es)
BR (1) BR112021012134A2 (es)
CA (1) CA3124260C (es)
CY (1) CY1126054T1 (es)
DK (1) DK3897697T3 (es)
EA (1) EA202191758A1 (es)
ES (1) ES2948264T3 (es)
FI (1) FI3897697T3 (es)
HR (1) HRP20230591T1 (es)
HU (1) HUE062537T2 (es)
IL (1) IL284029B2 (es)
LT (1) LT3897697T (es)
MX (1) MX2021007460A (es)
PL (1) PL3897697T3 (es)
PT (1) PT3897697T (es)
RS (1) RS64265B1 (es)
SG (1) SG11202107923WA (es)
SI (1) SI3897697T1 (es)
WO (1) WO2020127904A1 (es)
ZA (1) ZA202105101B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220061018A (ko) 2020-11-05 2022-05-12 한국생명공학연구원 항염 및 조직 재생작용을 갖는 신규 펩타이드
WO2023214802A1 (ko) 2022-05-03 2023-11-09 한국생명공학연구원 신규 펩타이드 및 이의 항염 및 재생 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6059099A (en) * 1998-09-25 2000-04-17 Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
EP1638963B1 (en) 2003-05-20 2009-09-09 Novartis AG N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
ATE401054T1 (de) 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen
KR100983746B1 (ko) 2005-01-14 2010-09-24 카무러스 에이비 소마토스타틴 유사 제형
WO2007000770A2 (en) * 2005-06-29 2007-01-04 Hadasit Medical Research Services & Development Ltd. Protein kinase c inhibitors for prevention of insulin resistance and type 2 diabetes
WO2010011313A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligation of stapled polypeptides
US8586707B2 (en) 2008-09-16 2013-11-19 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
US10821159B2 (en) * 2014-01-29 2020-11-03 Universite De Strasbourg Target for diabetes treatment and prevention
EP3421485A1 (en) * 2017-06-30 2019-01-02 Université de Strasbourg Peptides for treatment and prevention of hyperglycaemia
KR20200098640A (ko) * 2017-12-14 2020-08-20 위니베르시떼 드 스트라스부르 비알코올성 지방간 질환 및 섬유증의 치료 및 예방을 위한 펩타이드
EP3743092A4 (en) * 2018-01-23 2021-10-20 Gila Therapeutics, Inc. PHARMACEUTICAL PEPTIDE-YY FORMULATIONS, COMPOSITIONS, AND PROCEDURES

Also Published As

Publication number Publication date
WO2020127904A1 (en) 2020-06-25
LT3897697T (lt) 2023-07-10
ES2948264T3 (es) 2023-09-07
US20220133860A1 (en) 2022-05-05
PT3897697T (pt) 2023-06-27
HRP20230591T1 (hr) 2023-09-15
BR112021012134A2 (pt) 2021-09-08
EP4233890A3 (en) 2023-10-11
DK3897697T3 (da) 2023-06-26
IL284029B1 (en) 2023-05-01
IL284029A (en) 2021-08-31
SI3897697T1 (sl) 2023-10-30
AU2019408382A1 (en) 2021-08-12
CN116196399A (zh) 2023-06-02
EP3897697B1 (en) 2023-03-29
RS64265B1 (sr) 2023-07-31
FI3897697T3 (fi) 2023-06-21
KR102555817B1 (ko) 2023-07-13
EP3897697A1 (en) 2021-10-27
ZA202105101B (en) 2023-10-25
SG11202107923WA (en) 2021-08-30
EA202191758A1 (ru) 2021-10-01
PL3897697T3 (pl) 2023-07-24
KR20230110659A (ko) 2023-07-24
CA3124260A1 (en) 2020-06-25
HUE062537T2 (hu) 2023-11-28
IL284029B2 (en) 2023-09-01
CY1126054T1 (el) 2023-11-15
CA3124260C (en) 2023-01-03
EP4233890A2 (en) 2023-08-30
KR20210106520A (ko) 2021-08-30
CN113301916A (zh) 2021-08-24
CN113301916B (zh) 2023-01-03
JP2023159268A (ja) 2023-10-31
JP2022516012A (ja) 2022-02-24
JP7335337B2 (ja) 2023-08-29

Similar Documents

Publication Publication Date Title
MD3804737T2 (ro) Compoziții care conțin tulpini bacteriene
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
PH12018500016A1 (en) Agents, uses and methods for the treatment of synucleinopathy
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
MX2023005484A (es) Analogos de carbamoil fenilalaninol y usos de los mismos.
PH12019500751A1 (en) Carbamoyl phenylalaninol compounds and uses thereof
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
MX2020007555A (es) Anticuerpos potenciadores del factor h y usos de los mismos.
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2022013283A (es) Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales.
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
MX2017006692A (es) Trastornos neurodegenerativos.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
GB2574747A (en) Use of lambda interferons in the treatment of obesity-related disorders and related diseases
PH12017501918A1 (en) Multi-peptide composition
EA201992647A1 (ru) Композиции, содержащие бактериальные штаммы